Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine
- Department: Pediatrics
- Division: Oncology
- Primary Address:
The Children's Hospital of Philadelphia
Division of Oncology, 4028 CTRB
3501 Civic Center Boulevard
Philadelphia, PA 19104
Pediatric Oncology and Neuro-Oncology
Signal transduction in embryonal tumors of the developing nervous system. My laboratory work involves the study of receptor tyrosine kinase expression and inhibition in medulloblastoma
Signal transduction in neuroblastoma and medulloblastoma
- Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (2006 – present)
- Ph.D., Neurobiology, Yale University (1996)
- M.D., Medicine, Yale University School of Medicine (1996)
- M.Phil., Neurobiology, Yale University (1993)
- B.S., Psychobiology, Univeristy of Southern California (1986)
I'm part of a small group that focuses specifically on brain tumors. Our multidisciplinary team includes oncologists, a neurologist, neurosurgeons, a radiation oncologist, social workers and a neuropsychologist, along with skilled nurse practitioners. This is the broad spectrum of expertise that The Children's Hospital of Philadelphia brings to treating its patients with brain tumors.
Treating cancer is a team effort at Children's Hospital, and we consider patients and their families a part of the team. Since our young patients are dependent on their parents for medical decision making, I try to give them a sense of some control over their disease, communicating in an age appropriate manner. Kids do much better, even when facing death, when they are part of the treatment plan and "secrets" are not kept from them.
I do both basic science and clinical research that focuses on developmental therapeutics in tumors of the nervous system. In particular I and my colleagues are looking at signal transduction in neuroblastoma and medulloblastoma. We are evaluating the biological effects of neurotrophin receptor expression on the growth properties of these tumors. Neurotrophins are able to signal certain cells to survive, mature or grow. The Trk family of neurotrophin receptors plays a critical role in these diverse behaviors.
We recently completed a clinical trial that targeted these receptors to inhibit signaling in neuroblastoma. The results are promising that this could be a therapeutic target for high risk neuroblastoma. We also are studying the way that Trk receptor molecules located on the surface of medulloblastoma cells regulate tumor growth and development. These studies may help to identify new therapeutic targets in the Trk signaling pathways.
As part of our approach to identifying new treatments for children with brain tumors, we are members of the multi-institutional Pediatric Brain Tumor Consortium (PBTC) and the Developmental Therapeutics Children's Oncology Group. These groups are involved in early phase clinical trials for relapsing and refractory brain tumors, with a particular focus on testing new, targeted treatments in children with brain tumors.
Our Children's Hospital team has partnered with drug development groups, and we are rapidly identifying drugs that show promise in patients with brain tumors who have no other curable option. There is a sense of urgency in our group -- we don't randomly test drugs but work collaboratively with laboratory scientists and drug development companies on rational, biologically-based targets. The best example of this is a drug for medulloblastoma that was recently rapidly brought to a PBTC clinical trial.
There is huge progress in getting promising drugs to kids with cancer. Through our cooperative group consortia, the pace is much more rapid than in past years, and Children's Hospital is a major part of the effort to help bring new agents to children with brain tumors.
- Iyer Radhika, Evans Audrey E, Qi Xiaoxue, Ho Ruth, Minturn Jane E, Zhao Huaqing, Balamuth Naomi, Maris John M, Brodeur Garrett M. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. Vol 16(5) . 2010 Mar:1478-85.
- Russell-Swetek A, West AN, Minturn JE, Jenkins J, Rodriguez-Galindo C, Ribeiro R, Zambetti GP. Identification of a novel TP53 germline mutation E285V in a rare case of pediatric adrenocortical carcinoma and choroid plexus carcinoma. Journal of Medical Genetics. 2008.
- Ho R, Minturn JE, Simpson AM, Iyer R, Light JE, Evans AE, Brodeur GM. The effect of P75 on Trk receptors in neuroblastomas. Journal of Neuroscience Research. 2008.
- Wei Z, Minturn JE, Rappaport E, Brodeur G, Li H. Incorporation of genetic pathway information into analysis of multivariate gene expression data.. Biometrics. 2008.
- Ho R., Minturn JE., Hishiki T., Zhao H., Wang Q., Cnaan A., Maris J., Evans AE., Brodeur GM.. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Research. Vol 65(21) . 2005 Nov 1:9868-75.
- Ho R., Eggert A., Hishiki T., Minturn JE., Ikegaki N., Foster P., Camoratto AM., Evans AE., Brodeur GM.. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Research. Vol 62(22) . 2002 Nov 15:6462-6.
- Minturn JE., Fryer HJ., Geschwind DH., Hockfield S.. TOAD-64, a gene expressed early in neuronal differentiation in the rat, is related to unc-33, a C. elegans gene involved in axon outgrowth. Journal of Neuroscience. Vol 15(10) . 1995 Oct:6757-66.
- Black JA., Westenbroek R., Minturn JE., Ransom BR., Catterall WA., Waxman SG.. Isoform-specific expression of sodium channels in astrocytes in vitro: immunocytochemical observations. GLIA. Vol 14(2) . 1995 Jun:133-44.
- Minturn JE., Geschwind DH., Fryer HJ., Hockfield S.. Early postmitotic neurons transiently express TOAD-64, a neural specific protein. Journal of Comparative Neurology. Vol 355(3) . 1995 May 8:369-79.
- Minturn JE., Sontheimer H., Black JA., Ransom BR., Waxman SG.. Sodium channel expression in optic nerve astrocytes chronically deprived of axonal contact. GLIA. Vol 6(1) . 1992:19-29.